Current Infectious Disease Reports

, Volume 9, Issue 2, pp 151–158

Human papillomavirus vaccine update



With the approval of Gardasil® (Merck and Co., Inc., Whitehouse Station, NJ) in June of 2006 and the pending approval of Cervarix® (GlaxoSmithKline, London, UK), two prophylactic human papillomavirus (HPV) vaccines will be available for clinical use. Randomized controlled trials have shown that both vaccines are safe and highly effective in preventing persistent infection and lesions caused by HPV 16 and 18—the types responsible for 70% of cervical cancers worldwide. Determining an effective vaccination strategy is now the most pressing issue facing clinicians, parents, public health officials, and policy makers. We discuss the appropriate age of vaccination, vaccine acceptance, implementation strategies in low resource settings, and the future of screening.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Parkin DM, Bray F, Ferlay J, Pisani P: Global cancer statistics, 2002. CA Cancer J Clin 2005, 55:74–108.PubMedCrossRefGoogle Scholar
  2. 2.
    Denny L, Quinn M, Sankaranarayanan R: Chapter 8: Screening for cervical cancer in developing countries. Vaccine 2006, 24(Suppl 3):S71–77.CrossRefGoogle Scholar
  3. 3.
    Gravitt P, Shah K: A virus-based vaccine may prevent cervical cancer. Curr Infect Dis Rep 2005, 7:125–131.PubMedCrossRefGoogle Scholar
  4. 4.
    Koutsky LA, Ault KA, Wheeler CM, et al.: A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med 2002, 347:1645–1651.PubMedCrossRefGoogle Scholar
  5. 5.
    Koutsky LA, Harper DM: Chapter 13: Current findings from prophylactic HPV vaccine trials. Vaccine 2006, 24(Suppl 3):S114–121.CrossRefGoogle Scholar
  6. 6.
    Gardasil Prescribing Information. Available at Accessed December 7, 2006.
  7. 7.
    Hildesheim A, Herrero R: Effect of a HPV 16/18 vaccine on resolution of infections in women with pre-existing HPV. Presented at the 23rd International Papillomavirus Conference & Clinical Workshop. Prague, Czech Republic; September 1–7, 2006.Google Scholar
  8. 8.
    Stanley M, Lowy DR, Frazer I: Chapter 12: Prophylactic HPV vaccines: Underlying mechanisms. Vaccine 2006, 24(Suppl 3):S106–113.CrossRefGoogle Scholar
  9. 9.
    Harper DM, Franco EL, Wheeler CM, et al.: Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 2006, 367:1247–1255.PubMedCrossRefGoogle Scholar
  10. 10.
    Villa LL, Ault KA, Giuliano AR, et al.: Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18. Vaccine 2006, 24:5571–5583.PubMedCrossRefGoogle Scholar
  11. 11.
    Clifford G, Franceschi S, Diaz M, et al.: Chapter 3: HPV type-distribution in women with and without cervical neoplastic diseases. Vaccine 2006, 24(Suppl 3):S26–34.CrossRefGoogle Scholar
  12. 12.
    Palefsky JM, Gillison ML, Strickler HD: Chapter 16: HPV vaccines in immunocompromised women and men. Vaccine 2006, 24(Suppl 3):S140–146.CrossRefGoogle Scholar
  13. 13.
    Taira AV, Neukermans CP, Sanders GD: Evaluating human papillomavirus vaccination programs. Emerg Infect Dis 2004, 10:1915–1923.PubMedGoogle Scholar
  14. 14.
    Barnabas RV, Laukkanen P, Koskela P, et al.: Epidemiology of HPV 16 and cervical cancer in Finland and the potential impact of vaccination: mathematical modelling analyses. PLoS Med 2006, 3:e138.PubMedCrossRefGoogle Scholar
  15. 15.
    Roden RB, Yutzy WH, Fallon R, et al.: Minor capsid protein of human genital papillomaviruses contains subdominant, cross-neutralizing epitopes. Virology 2000, 270:254–257.PubMedCrossRefGoogle Scholar
  16. 16.
    Rose RC, White WI, Li M, et al.: Human papillomavirus type 11 recombinant L1 capsomeres induce virus-neutralizing antibodies. J Virol 1998, 72:6151–6154.PubMedGoogle Scholar
  17. 17.
    Roden R, Wu TC: Preventative and therapeutic vaccines for cervical cancer. Expert Rev Vaccines 2003, 2:495–516.PubMedCrossRefGoogle Scholar
  18. 18.
    Goldie SJ, Grima D, Kohli M, et al.: A comprehensive natural history model of HPV infection and cervical cancer to estimate the clinical impact of a prophylactic HPV-16/18 vaccine. Int J Cancer 2003, 106:896–904.PubMedCrossRefGoogle Scholar
  19. 19.
    Goldie SJ, Kohli M, Grima D, et al.: Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine. J Natl Cancer Inst 2004, 96:604–615.PubMedCrossRefGoogle Scholar
  20. 20.
    Kulasingam SL, Myers ER: Potential health and economic impact of adding a human papillomavirus vaccine to screening programs. JAMA 2003, 290:781–789.PubMedCrossRefGoogle Scholar
  21. 21.
    Merck and Co. Inc.: European Commission approves GARDASIL®, Merck’s cervical cancer vaccine [press release]. Available at Accessed December 7, 2006.
  22. 22.
    ACIP provisional recommendations for the use of quadrivalent HPV vaccine. Available at Accessed December 7, 2006.
  23. 23.
    Gravitt PE, Viscidi RP: Shah KV}. Dordrecht/Boston/London: Kluwer Academic Publishers; 2004:119–141.CrossRefGoogle Scholar
  24. 24.
    Winer RL, Lee SK, Hughes JP, et al.: Genital human papillomavirus infection: incidence and risk factors in a cohort of female university students. Am J Epidemiol 2003, 157:218–226.PubMedCrossRefGoogle Scholar
  25. 25.
    Eaton DK, Kann L, Kinchen S, et al.: Youth risk behavior surveillance—United States, 2005. MMWR Surveill Summ 2006, 55:1–108.PubMedGoogle Scholar
  26. 26.
    Zimet GD, Liddon N, Rosenthal SL, et al.: Chapter 24: Psychosocial aspects of vaccine acceptability. Vaccine 2006, 24(Suppl 3):S201–209.CrossRefGoogle Scholar
  27. 27.
    Advisory Committee on Immunization Practices, Vaccines for Children Program: Vaccine to prevent human papillomavirus infection. Available at Accessed December 7, 2006.
  28. 28.
    PATH: PATH to pave the way for cervical cancer vaccines in the developing world [press release]. Available at Accessed December 7, 2006.
  29. 29.
    Franco EL, Bosch FX, Cuzick J, et al.: Chapter 29: Knowledge gaps and priorities for research on prevention of HPV infection and cervical cancer. Vaccine 2006, 24(Suppl 3):S242–249.CrossRefGoogle Scholar
  30. 30.
    Garnett GP, Kim JJ, French K, Goldie SJ: Chapter 21: Modelling the impact of HPV vaccines on cervical cancer and screening programmes. Vaccine 2006, 24(Suppl 3):S178–186.CrossRefGoogle Scholar
  31. 31.
    Cuzick J, Mayrand MH, Ronco G, et al.: Chapter 10: New dimensions in cervical cancer screening. Vaccine 2006, 24(Suppl 3):S90–97.CrossRefGoogle Scholar
  32. 32.
    Arbyn M, Sasieni P, Meijer CJ, et al.: Chapter 9: Clinical applications of HPV testing: A summary of meta-analyses. Vaccine 2006, 24(Suppl 3):S78–89.CrossRefGoogle Scholar
  33. 33.
    Cuzick J, Szarewski A, Cubie H, et al.: Management of women who test positive for high-risk types of human papillomavirus: the HART study. Lancet 2003, 362:1871–1876.PubMedCrossRefGoogle Scholar
  34. 34.
    Harper DM, Franco EL, Wheeler C, et al.: Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 2004, 364:1757–1765.PubMedCrossRefGoogle Scholar

Copyright information

© Current Medicine Group, LLC 2007

Authors and Affiliations

  1. 1.Department of Epidemiology and Molecular Microbiology and ImmunologyJohns Hopkins Bloomberg School of Public HealthBaltimoreUSA

Personalised recommendations